NRAS and melanoma: To examine the antiproliferative effects of CH5126766 or PD0325901, we used two melanoma cell lines with mutations resulting in ERK activation, SK-MEL-28 (BRAF V600E), and SK-MEL-2 (NRAS Q61R).